Cocktail-substrate Approach-based High-throughput Assay for Evaluation of Direct and Time-dependent Inhibition of Multiple Cytochrome P450 Isoforms

被引:31
作者
Kozakai, Kazumasa [1 ]
Yamada, Yasuhiro [1 ]
Oshikata, Motoji [2 ]
Kawase, Taiji [2 ]
Suzuki, Etsuko [2 ]
Haramaki, Yukari [2 ]
Taniguchi, Hideki [1 ]
机构
[1] Yokohama City Univ, Sch Med, Dept Regenerat Med, Yokohama, Kanagawa 2360004, Japan
[2] Nihon Waters KK, Solut Ctr, Tokyo, Japan
关键词
CYP inhibition; direct inhibition; time-dependent inhibition; IC50-shift; UPLC-MS/MS; cocktail approach; drug-drug interaction; HUMAN LIVER-MICROSOMES; DRUG-DRUG INTERACTIONS; IN-VITRO; METABOLISM; DISCOVERY; ENZYMES; CYP3A4; CHLORZOXAZONE; CYP2C19; CYP2E1;
D O I
10.2133/dmpk.DMPK-13-RG-093
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Avoiding drug-drug interactions (DDIs) mediated through inhibition of cytochrome P450 (CYP) activity is highly desirable. Direct inhibition (DI) of CYP through new chemical entities (NCEs) or time-dependent inhibition (TDI) through reactive metabolites should be elucidated at an early stage of drug discovery research. In particular, TDI of CYP occurring through reactive metabolites may be irreversible and even sustained, causing far more serious DDIs for TDIs than for DIs. Furthermore, it is important to ascertain whether an NCE inhibits multiple CYP isoforms. Hence, using a cocktail-substrate approach that we previously established (in which the activity of 8 CYP isoforms is simultaneously evaluated in a single run), we evaluated the IC50 values of direct inhibitors and TDI parameters (k(obs), shifted IC50, K-I and k(inact)) of time-dependent inhibitors that affect multiple CYP isoforms. The IC50 values for 8 CYP isoforms obtained using the cocktail-substrate approach were nearly identical to values previously reported. The TDI parameters for CYP1A2, 2C9, 2C19, 2D6, and CYP3A4/5 obtained using the cocktail-substrate approach were also nearly identical to those obtained using a single-substrate approach. Thus, the cocktail-substrate approach is useful for evaluating DI and TDI in the early stages of drug discovery and development processes.
引用
收藏
页码:198 / 207
页数:10
相关论文
共 31 条
[11]   Reliable High-throughput Method for Inhibition Assay of 8 Cytochrome P450 Isoforms Using Cocktail of Probe Substrates and Stable Isotope-labeled Internal Standards [J].
Kozakai, Kazumasa ;
Yamada, Yasuhiro ;
Oshikata, Motoji ;
Kawase, Taiji ;
Suzuki, Etsuko ;
Haramaki, Yukari ;
Taniguchi, Hideki .
DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (05) :520-529
[12]   Timing of new black box warnings and withdrawals for prescription medications [J].
Lasser, KE ;
Allen, PD ;
Woolhandler, SJ ;
Himmelstein, DU ;
Wolfe, SN ;
Bor, DH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (17) :2215-2220
[13]   Cytochrome p450 specificity of metabolism and interactions of oxybutynin in human liver microsomes [J].
Lukkari, E ;
Taavitsainen, P ;
Juhakoski, A ;
Pelkonen, O .
PHARMACOLOGY & TOXICOLOGY, 1998, 82 (04) :161-166
[14]   Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development [J].
Mori, K. ;
Hashimoto, H. ;
Takatsu, H. ;
Tsuda-Tsukimoto, M. ;
Kume, T. .
XENOBIOTICA, 2009, 39 (06) :415-422
[15]   Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes [J].
Niwa, T ;
Shiraga, T ;
Takagi, A .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (09) :1805-1808
[16]   Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions [J].
Obach, R. Scott ;
Walsky, Robert L. ;
Venkatakrishnan, Karthik .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (02) :246-255
[17]   CHLORZOXAZONE IS METABOLIZED BY HUMAN CYP1A2 AS WELL AS BY HUMAN CYP2E1 [J].
ONO, S ;
HATANAKA, T ;
HOTTA, H ;
TSUTSUI, M ;
SATOH, T ;
GONZALEZ, FJ .
PHARMACOGENETICS, 1995, 5 (03) :143-150
[18]   An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A) [J].
Palmer, JL ;
Scott, RJ ;
Gibson, A ;
Dickins, M ;
Pleasance, S .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (05) :555-561
[19]   An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes [J].
Parkinson, Andrew ;
Kazmi, Faraz ;
Buckley, David B. ;
Yerino, Phyllis ;
Paris, Brandy L. ;
Holsapple, Jeff ;
Toren, Paul ;
Otradovec, Steve M. ;
Ogilvie, Brian W. .
DRUG METABOLISM AND DISPOSITION, 2011, 39 (08) :1370-1387
[20]   Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo [J].
Peng, C-C ;
Templeton, I. ;
Thummel, K. E. ;
Davis, C. ;
Kunze, K. L. ;
Isoherranen, N. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) :888-895